Novel Topical Treatments for Psoriasis that are Safe & Effective
Novel topical treatments for psoriasis are reshaping care for patients seeking safer, more effective long-term relief. Psoriasis affects more than 7 million adults in the United States, causing chronic, often debilitating plaques that impact quality of life, self-esteem, and daily function. For decades, the mainstay of topical therapy consisted of corticosteroids, vitamin D analogs, and tar preparations: effective for many, but limited by side effects with long-term use, restricted use in sensitive areas, and suboptimal results for difficult-to-treat locations. That landscape is changing rapidly.
A new generation of non-steroidal topical treatments for psoriasis is transforming how dermatologists approach mild to moderate psoriasis, offering patients better safety profiles, novel mechanisms of action, and real improvements in disease control. At Trillium Clinic, a trusted dermatology clinic near Chapel Hill, we stay at the forefront of these advances to ensure our patients have access to the most current, evidence-based psoriasis treatment.
If you’re searching for a dermatologist near Chapel Hill or a dermatologist for psoriasis treatment near me, expert care can help you explore the newest options available.
Why Non-Steroidal Topicals Matter
The limitations of topical corticosteroids: skin atrophy, telangiectasias, adrenal suppression with prolonged use, and absolute contraindication in some body locations, have long frustrated both dermatologists and patients. Areas like skin folds, the face, and genitalia require gentler options, and patients with pediatric psoriasis face even stricter constraints.
Non-steroidal topical treatments for psoriasis offer a path forward: treatments that can be used in sensitive zones, applied over longer time periods, and employed without the taper protocols often needed with steroids. For many patients seeking modern psoriasis treatment, these newer therapies provide safer maintenance options and improved quality of life. A personalized topical psoriasis treatment consultation can help determine which option best fits your skin type, body areas involved, and treatment goals.
Roflumilast Cream and Foam: A First-in-Class PDE4 Inhibitor
One of the most significant recent breakthroughs in novel topical treatments for psoriasis is roflumilast (brand name Zoryve), a topical phosphodiesterase 4 (PDE4) inhibitor. PDE4 is an enzyme that degrades cyclic adenosine monophosphate (cAMP), a molecule that normally acts as a brake on inflammation. When PDE4 is active, pro-inflammatory mediators accumulate in the skin. By blocking PDE4, roflumilast raises intracellular cAMP levels, reducing the release of cytokines that drive psoriatic plaques.
Roflumilast cream 0.3% received FDA approval in 2022 for adults and adolescents with plaque psoriasis, and a landmark expansion followed in October 2023 when it became the first non-steroidal topical treatment for psoriasis approved for children aged 6 years and older – a population that previously had no FDA-approved non-steroidal topical options. Clinical trial data published in the New England Journal of Medicine demonstrated robust efficacy, with substantial proportions of patients achieving Investigator Global Assessment (IGA) success compared to vehicle.
What makes roflumilast especially notable is its demonstrated efficacy in intertriginous psoriasis – psoriasis in the folds of the skin, such as the groin, underarms, and beneath the breasts. These areas are traditionally difficult to treat because superpotent steroids are contraindicated there, and other options often fail. Roflumilast is the only topical psoriasis treatment that has been specifically studied and demonstrated to be effective in intertriginous disease, making it a genuine advance for patients with this difficult-to-treat location.
Beyond the cream formulation, roflumilast foam 0.3% has emerged as another important development in novel topical treatments for psoriasis. The foam vehicle is particularly suited for scalp and body psoriasis, where creams may be difficult to apply through hair. Phase 3 data from the ARRECTOR trial program showed significant efficacy for scalp psoriasis, with nearly 60% of foam-treated patients achieving meaningful endpoints compared to roughly 11% with vehicle at week 8.
The foam formulation was approved in 2025, addressing an important unmet need for patients with scalp involvement – one of the most common and burdensome psoriasis locations. For patients seeking updated psoriasis treatment strategies, this newer formulation offers a practical solution for difficult-to-treat hair-bearing areas. A visit to a psoriasis treatment clinic in Chapel Hill or consultation with a board-certified dermatologist near Chapel Hill can help determine if roflumilast foam is appropriate for your condition.
Tapinarof Cream: A Novel AhR Modulator
Tapinarof cream 1% (brand name Vtama) represents a completely different and first-in-class mechanism of action among novel topical treatments for psoriasis. Tapinarof is a therapeutic aryl hydrocarbon receptor (AhR) modulating agent. The aryl hydrocarbon receptor regulates immune responses and skin barrier function; when activated by tapinarof, it normalizes the inflammatory pathways driving psoriasis and strengthens the skin’s natural barrier.
This mechanism is unrelated to corticosteroids, calcineurin inhibitors, or PDE4 inhibition, making tapinarof a genuinely novel approach within non-steroidal topical treatments for psoriasis. For patients who need alternatives to steroid-based psoriasis treatment, this can be an important advance.
Tapinarof received FDA approval in 2022 for adults with plaque psoriasis and has since accumulated additional real-world data confirming its clinical trial results. Three phase 3 trials demonstrated significant improvements in PASI scores (Psoriasis Area and Severity Index), and the once-daily application schedule supports patient adherence.
Since tapinarof works through a distinct mechanism, it can potentially be used in patients who have not responded to or who are not candidates for other topical therapies. It has also been associated with a ‘remittive effect’ in some patients – a prolonged period of disease control even after stopping treatment, a phenomenon not seen with conventional topical steroids. Patients interested in newer therapies may benefit from a topical psoriasis treatment consultation with a specialist.
Topical JAK Inhibitors: Ruxolitinib and Beyond
The Janus kinase (JAK) inhibitor class has revolutionized systemic treatment of inflammatory skin diseases, and topical formulations are now extending these benefits to patients with localized disease. These emerging therapies may become valuable additions to novel topical treatments for psoriasis as more evidence develops.
Ruxolitinib cream 1.5% (Opzelura) is a topical JAK1/JAK2 inhibitor initially approved for atopic dermatitis and is increasingly being explored off-label and in formal studies for psoriasis. Its ability to block the JAK-STAT signaling pathway, which transmits signals from key pro-inflammatory cytokines including IL-4, IL-13, and interferons, makes it mechanistically relevant to psoriatic inflammation.
Delgocitinib, a pan-JAK inhibitor (targeting JAK1, JAK2, JAK3, and TYK2), has demonstrated efficacy in psoriasis and related inflammatory skin conditions in clinical settings outside the United States. As data mature, topical JAK inhibitors may represent an additional class of non-steroidal topical treatments for psoriasis, particularly for patients with comorbid atopic conditions or those seeking alternatives to the currently approved options.
If you are searching for a dermatologist for psoriasis treatment near me or a trusted dermatology clinic near Chapel Hill, expert guidance can help determine whether these evolving therapies fit into your personalized treatment plan.
Looking Ahead: Personalized Topical Therapy
The psoriasis treatment landscape reflects a clear trend: moving away from broad, non-specific anti-inflammatory approaches (particularly long-term steroid use) toward targeted therapies that modulate specific inflammatory pathways with greater precision and fewer systemic risks. Expert panels and international treatment guidelines have begun formalizing recommendations for transitioning patients from corticosteroids to these novel topical treatments for psoriasis when appropriate.
For patients, this means more choices, better options for sensitive skin areas, and pediatric-specific approvals that have previously been lacking. For dermatologists, it means a richer toolkit to individualize care: matching the mechanism of action to the patient’s specific disease pattern, body location, comorbidities, and preferences.
Talk to Your Dermatologist
If you are living with psoriasis and feel that your current topical regimen is not adequately controlling your symptoms, or if you are experiencing side effects from long-term steroid use, it may be time to discuss these novel topical treatments for psoriasis. Roflumilast cream or foam, tapinarof, and emerging topical JAK inhibitors each offer distinct advantages depending on the location and severity of your psoriasis.
At Trillium Dermatology, our board-certified dermatologists are experienced in diagnosing and treating all forms of psoriasis, including plaque, guttate, inverse, and pustular variants. We work closely with each patient to develop a personalized, evidence-based psoriasis treatment plan designed around your goals, medical history, and skin needs. Contact us today to schedule a consultation and discover how our team can help.
FAQs
They are newer prescription creams, foams, and ointments designed to target specific inflammatory pathways involved in psoriasis. Examples include roflumilast, tapinarof, and emerging JAK inhibitor therapies. These treatments often provide effective control with fewer limitations than older steroid-based options.
Yes. Many of them have shown strong clinical results in reducing plaque thickness, redness, itching, and scaling. They can be especially helpful for sensitive areas such as the face, skin folds, and genital regions, where long-term steroid use may be less ideal.
Patients with mild to moderate psoriasis, those experiencing side effects from steroid creams, or individuals needing safer long-term maintenance options may benefit. A topical psoriasis treatment consultation with a dermatologist can help determine the best fit for your skin type, body areas affected, and treatment goals.
Topical therapies mainly improve skin symptoms and are not usually the best treatment for psoriatic arthritis on their own. Joint symptoms often require systemic medications or coordinated care with a rheumatologist. If you have joint pain, stiffness, or swelling, speak with your provider promptly.
